계명대학교 의학도서관 Repository

Temporal modulation (early escalation and late de-escalation) of antiplatelet therapy in patients undergoing complex high-risk PCI: rationale and design of the TAILORED-CHIP trial

Metadata Downloads
Author(s)
Hanbit ParkDo-Yoon KangJung-Min AhnSung-Cheol YunKyoung-Ha ParkSe-Hun KangJon SuhJang-Whan BaeSangwoo ParkJang Hyun ChoJung-Won SuhBong-Ki LeeSeung-Woon RhaHoyoun WonJae-Sik JangMoo Hyun KimCheol Hyun LeeYoung Keun AhnJun-Hyok OhJae-Seok BaeChul Soo ParkJaewoong ChoiJin-Bae LeeSe-Whan LeeSung-Ho HurOsung KwonSeung-Jung ParkDuk-Woo Park
Keimyung Author(s)
Lee, Cheol Hyun
Department
Dept. of Internal Medicine (내과학)
Journal Title
EuroIntervention
Issued Date
2024
Volume
20
Issue
21
Abstract
Despite the use of conventional dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), the risk of adverse events remains high among patients with increased thrombotic risk. Until recently, the optimal antiplatelet strategy to balance the ischaemic and bleeding risks in patients who are undergoing complex high-risk PCI has been unclear. The TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (TAILORED-CHIP) trial is an investigator-initiated, multicentre, prospective randomised trial to evaluate the efficacy and safety of a time-dependent tailored antiplatelet therapy with an early (<6 months post-PCI) escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin) and a late (>6 months post-PCI) de-escalation (clopidogrel monotherapy) in patients undergoing complex high-risk PCI as compared with standard DAPT (clopidogrel plus aspirin for 12 months). Eligible patients had to have at least one high-risk anatomical or procedural feature or clinical characteristic associated with an increased risk of ischaemic or thrombotic events. The primary endpoint was the net clinical outcome, a composite of death from any cause, myocardial infarction, stroke, stent thrombosis, urgent revascularisation, or clinically relevant bleeding (Bleeding Academic Research Consortium type 2, 3, or 5) at 12 months after randomisation. (ClinicalTrials.gov: NCT03465644)
Keimyung Author(s)(Kor)
이철현
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
1969-6213
Source
https://eurointervention.pcronline.com/article/temporal-modulation-early-escalation-and-late-de-escalation-of-antiplatelet-therapy-in-patients-undergoing-complex-high-risk-pci-rationale-and-design-of-the-tailored-chip-trial
DOI
10.4244/EIJ-D-24-00437
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/46009
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.